<DOC>
	<DOCNO>NCT00864136</DOCNO>
	<brief_summary>The aim prospective , non-interventional post-marketing surveillance study obtain data safety efficacy Mirena treatment prolong heavy menstrual bleeding ( Menorrhagia ) daily-life treatment condition . It plan conduct study 10 country total 1000 patient . In several country , comparator group also document . For patient , initial visit one three follow-up visit 3 , 6 12 month document treat physician case report form . Observations include patient 's demographic parameter ( date birth , height , weight , race smoking habit ) , previous contraceptive menorrhagia treatment , gynaecological history , baseline menstruation , result insertion , concomitant medication diseases well menorrhagia symptom . Overall treatment success evaluate end treatment include number week improvement reduction menstrual bleeding respect duration severity , patient 's satisfaction .</brief_summary>
	<brief_title>Mirena Conventional Medical Treatment Menorrhagia</brief_title>
	<detailed_description>The `` MiCo - Mirena conventional medical treatment menorrhagia '' study consist two part , MiCo Asia-Pacific MiCo MA0901 ( Rest World ) . Data part analyse separate pool well global pool . The trial alias IMPACT Nos . 14697 , 14536 ( NCT01085487 ) .</detailed_description>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<criteria>Women age 1845 ( inclusive ) intend get pregnant next year Women complain heavy menstrual bleed several consecutive cycle Women without structural histological abnormality uterus , fibroid less 3 cm diameter cause distortion uterine cavity ( eligible pharmaceutical treatment accord NICE guideline 2007 ) Informed consent ( require law regulation ) The contraindication warning respective Summary Product Characteristics ( Mirena , combine oral contraceptive , oral/injectable progestogen , nonsteroidal antiinflammatory drug , antifibrinolytic agent ) must follow . Women take hormone replacement therapy Women symptom intermenstrual postcoital bleeding , unless endometrial biopsy perform pathology exclude Women fibroid palpable abdominally intracavity fibroid and/or whose uterine length measure ultrasound hysteroscopy great 12 cm ( NICE guideline 2007 ) Women anticoagulative therapy treatment ( include e.g . Copper IUD use ) know cause menorrhagia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>